Literature DB >> 26984993

Empiric antibiotic treatment for urinary tract infection in preschool children: susceptibilities of urine sample isolates.

Christopher C Butler1, Kathryn O'Brien2, Mandy Wootton3, Timothy Pickles3, Kerenza Hood4, Robin Howe3, Cherry-Ann Waldron4, Emma Thomas-Jones4, Jan Dudley5, Judith Van Der Voort6, Kate Rumsby7, Paul Little7, Harriet Downing8, Kim Harman7, Alastair D Hay8.   

Abstract

BACKGROUND: Antibiotic treatment recommendations based on susceptibility data from routinely submitted urine samples may be biased because of variation in sampling, laboratory procedures and inclusion of repeat samples, leading to uncertainty about empirical treatment.
OBJECTIVE: To describe and compare susceptibilities of Escherichia coli cultured from routinely submitted samples, with E. coli causing urinary tract infection (UTI) from a cohort of systematically sampled, acutely unwell children.
METHODS: Susceptibilities of 1458 E. coli isolates submitted during the course of routine primary care for children <5 years (routine care samples), compared to susceptibilities of 79 E. coli isolates causing UTI from 5107 children <5 years presenting to primary care with an acute illness [systematic sampling: the Diagnosis of Urinary Tract infection in Young children (DUTY) cohort].
RESULTS: The percentage of E. coli sensitive to antibiotics cultured from routinely submitted samples were as follows: amoxicillin 45.1% (95% confidence interval: 42.5-47.7%); co-amoxiclav using the lower systemic break point (BP) 86.6% (84.7-88.3%); cephalexin 95.1% (93.9-96.1%); trimethoprim 74.0% (71.7-76.2%) and nitrofurantoin 98.2% (97.4-98.8%). The percentage of E. coli sensitive to antibiotics cultured from systematically sampled DUTY urines considered to be positive for UTI were as follows: amoxicillin 50.6% (39.8-61.4%); co-amoxiclav using the systemic BP 83.5% (73.9-90.1%); co-amoxiclav using the urinary BP 94.9% (87.7-98.4%); cephalexin 98.7% (93.2-99.8%); trimethoprim 70.9% (60.1-80.0%); nitrofurantoin 100% (95.3-100.0%) and ciprofloxacin 96.2% (89.4-98.7%).
CONCLUSION: Escherichia coli susceptibilities from routine and systematically obtained samples were similar. Most UTIs in preschool children remain susceptible to nitrofurantoin, co-amoxiclav and cephalexin.
© The Author 2016. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Antibacterial agents; antibiotic resistance; diagnosis; paediatrics; surveillance; treatment recommendations; urinary tract infections.

Mesh:

Substances:

Year:  2016        PMID: 26984993     DOI: 10.1093/fampra/cmv104

Source DB:  PubMed          Journal:  Fam Pract        ISSN: 0263-2136            Impact factor:   2.267


  4 in total

1.  Antibiotic resistance patterns of urinary tract pathogens in children from Central Romania.

Authors:  Carmen Duicu; Iulia Cozea; Dan Delean; Andreea Alexandra Aldea; Cornel Aldea
Journal:  Exp Ther Med       Date:  2021-05-12       Impact factor: 2.447

2.  Development and Validation of a Calculator for Estimating the Probability of Urinary Tract Infection in Young Febrile Children.

Authors:  Nader Shaikh; Alejandro Hoberman; Stephanie W Hum; Anastasia Alberty; Gysella Muniz; Marcia Kurs-Lasky; Douglas Landsittel; Timothy Shope
Journal:  JAMA Pediatr       Date:  2018-06-01       Impact factor: 16.193

3.  Study of the Antimicrobial Activity of the Chinese Dong Ethnic Minority Medicine, Madeng'ai.

Authors:  Zhenrong Tang; Yannan Zhao; Zaiqi Zhang; Huan Yue; Dan Wang; Shengchun Liu; Hua Tang
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-01       Impact factor: 2.650

4.  Urinary tract infections in children: building a causal model-based decision support tool for diagnosis with domain knowledge and prospective data.

Authors:  Jessica A Ramsay; Steven Mascaro; Anita J Campbell; David A Foley; Ariel O Mace; Paul Ingram; Meredith L Borland; Christopher C Blyth; Nicholas G Larkins; Tim Robertson; Phoebe C M Williams; Thomas L Snelling; Yue Wu
Journal:  BMC Med Res Methodol       Date:  2022-08-08       Impact factor: 4.612

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.